These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 16143421

  • 1. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
    Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H.
    J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
    [Abstract] [Full Text] [Related]

  • 2. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De la Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez-Rodríguez Mde L.
    Alcohol Alcohol; 2006 Dec; 41(3):261-6. PubMed ID: 16476762
    [Abstract] [Full Text] [Related]

  • 3. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F.
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [Abstract] [Full Text] [Related]

  • 4. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M, Owczarska K, Sokołowska U, Centkowski P, Pogłód R, Kruk B.
    Arch Immunol Ther Exp (Warsz); 2005 Apr; 53(5):454-64. PubMed ID: 16314829
    [Abstract] [Full Text] [Related]

  • 5. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [Abstract] [Full Text] [Related]

  • 6. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis.
    Bezerra MC, Calomeni GD, Caparbo VF, Gebrim ES, Rocha MS, Pereira RM.
    Rheumatology (Oxford); 2005 Dec; 44(12):1503-6. PubMed ID: 16219645
    [Abstract] [Full Text] [Related]

  • 7. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodés J, Guañabens N.
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [Abstract] [Full Text] [Related]

  • 8. Changes in osteoprotegerin/RANKL system, bone mineral density, and bone biochemicals markers in patients with recent spinal cord injury.
    Maïmoun L, Couret I, Mariano-Goulart D, Dupuy AM, Micallef JP, Peruchon E, Ohanna F, Cristol JP, Rossi M, Leroux JL.
    Calcif Tissue Int; 2005 Jun; 76(6):404-11. PubMed ID: 15812577
    [Abstract] [Full Text] [Related]

  • 9. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
    Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, Dimopoulos MA, Rahemtulla A.
    Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
    [Abstract] [Full Text] [Related]

  • 10. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L, Dolzani P, Silvestri T, Caraceni P, Facchini A, Ravaglia G, Salvarani C, Melicòni R, Mariani E.
    Biogerontology; 2004 Sep; 5(2):119-27. PubMed ID: 15105586
    [Abstract] [Full Text] [Related]

  • 11. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S.
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [Abstract] [Full Text] [Related]

  • 12. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
    Masi L, Simonini G, Piscitelli E, Del Monte F, Giani T, Cimaz R, Vierucci S, Brandi ML, Falcini F.
    J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
    [Abstract] [Full Text] [Related]

  • 13. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
    Minenna G, D'Amore S, Maggiolini P, Scagliusi P, D'Amore M.
    Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
    [Abstract] [Full Text] [Related]

  • 14. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.
    Steroids; 2005 Dec 01; 70(13):847-55. PubMed ID: 16005483
    [Abstract] [Full Text] [Related]

  • 15. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y, Onouchi T, Ikeda T, Adachi J, Tamura Y, Horiuchi T.
    Gerontology; 2009 Dec 01; 55(3):275-80. PubMed ID: 19158438
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction.
    Crisafulli A, Micari A, Altavilla D, Saporito F, Sardella A, Passaniti M, Raffa S, D'anneo G, Lucà F, Mioni C, Arrigo F, Squadrito F.
    Clin Sci (Lond); 2005 Oct 01; 109(4):389-95. PubMed ID: 15926884
    [Abstract] [Full Text] [Related]

  • 17. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
    Morena M, Terrier N, Jaussent I, Leray-Moragues H, Chalabi L, Rivory JP, Maurice F, Delcourt C, Cristol JP, Canaud B, Dupuy AM.
    J Am Soc Nephrol; 2006 Jan 01; 17(1):262-70. PubMed ID: 16280472
    [Abstract] [Full Text] [Related]

  • 18. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007 Jan 01; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 19. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E, Orive A, García-Unzueta M, Amado JA, Casafont F, Pons-Romero F.
    Clin Transplant; 2006 Jan 01; 20(3):383-8. PubMed ID: 16824158
    [Abstract] [Full Text] [Related]

  • 20. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
    Lu HK, Chen YL, Chang HC, Li CL, Kuo MY.
    J Periodontal Res; 2006 Aug 01; 41(4):354-60. PubMed ID: 16827732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.